abvc-logo-nasdaq-440x386 (1).png
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments
July 26, 2023 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
ARIDIS_LOGO.png
Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation
July 12, 2023 08:00 ET | Aridis Pharmaceuticals, Inc.
QIDP designation for Biologics provides FDA Priority Review status LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study
July 05, 2023 08:45 ET | Palisade Bio, Inc.
Topline data expected in Q3 2023 Carlsbad, CA, July 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute...
LOGO.png
GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders
July 05, 2023 08:33 ET | The Greater Cannabis Company, Inc.
BALTIMORE, July 05, 2023 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next...
ARIDIS_LOGO.png
Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)
June 20, 2023 08:00 ET | Aridis Pharmaceuticals, Inc.
LPAD may provide alternative pathways for streamlined product approval LOS GATOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis
June 20, 2023 08:00 ET | Timber Pharmaceuticals
- First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That Indicate Minimal Systemic Absorption of Isotretinoin - - Data to be Presented at the Society for...
Logo 1.png
Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders
June 14, 2023 16:05 ET | Aeterna Zentaris Inc
TORONTO, ONTARIO, June 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
June 14, 2023 08:45 ET | Palisade Bio, Inc.
Live webcast fireside chat on Thursday, June 22nd at 11:30 AM ET Carlsbad, CA, June 14, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a biopharmaceutical company advancing therapies...
ARIDIS_LOGO.png
Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update
June 08, 2023 16:05 ET | Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Promotes J.D. Finley to Chief Executive Officer
June 01, 2023 08:45 ET | Palisade Bio, Inc.
Carlsbad, CA, June 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic...